QuidelOrtho CorpQDEL

NasdaqHealthcareIn Vitro & In Vivo Diagnostic Substances
Price (close)
$10.69
Market cap
$733.1M
P/E
—
Revenue (TTM)
$2.7B
Net income
-$1.0B
Dividend yield
—
1-year total return
-59.7%
Net margin
-39.2%
Revenue growth
-2.5%
Debt / equity
1.63x

What QuidelOrtho Corp does.

All references to “the Company,” “we,” “our” and “us” in this Annual Report refer to QuidelOrtho Corporation (“QuidelOrtho”) and its subsidiaries. References to “fiscal year ended 2025,” “fiscal year ended 2024” and “fiscal year ended 2023” in this Annual Report refer to the Company’s fiscal years ended December 28, 2025, December 29, 2024 and December 31, 2023, respectively. Refer to the Summary of Abbreviated Terms at the end of this Annual Report for definitions of terms used throughout this Annual Report.

Our vision is to advance diagnostics to power a healthier future. With our expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, we aim to support clarity for clinicians and patients to help create better health outcomes. Our global infrastructure and commercial reach support our customers across more than 140 countries and territories with quality diagnostics, a broad test portfolio and market-leading service. We operate globally with manufacturing facilities in the U.S., U.K. and China and with sales centers, administrative offices and warehouses located throughout the world.

We currently sell our products directly to end users through a direct sales force and through a network of distributors, for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, other POC settings, blood banks and donor centers, as well as for individual, non-professional, OTC use.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$1.7B$1.7B$3.3B$3.0B$2.8B$2.7B
Net income$810.3M$704.2M$548.7M-$10.1M-$2.1B-$1.1B
Free cash flow$564.8M$513.1M$744.4M$70.9M-$112.1M-$83.0M

More on QDEL.

Figures from QuidelOrtho Corp's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.